By Nana O 
The landscape of cancer treatment has been dramatically reshaped by immunotherapies that empower the body’s own immune system to target and eliminate malignant cells. While these revolutionary approaches have shown remarkable success against certain blood and lymphatic cancers, solid tumors have persistently presented a formidable challenge. The intricate architecture of solid tumors often acts as a barrier, hindering the infiltration of immune cells, while simultaneously secreting a complex array of signals that actively suppress immune responses. Addressing this critical unmet need, researchers at Stanford Medicine, in collaboration with other leading institutions, have unveiled a pioneering strategy that engineers a specialized form of natural killer (NK) cells, equipping them to effectively penetrate and dismantle solid tumors.
This groundbreaking research, published last month in the esteemed journal Science Translational Medicine, details the development of tissue-resident NK cells, a subtype of immune cells renowned for their rapid and potent ability to identify and destroy abnormal cells. By transforming conventional NK cells into this specialized, tissue-homing variant, the Stanford-led team has created a therapeutic candidate with the potential to overcome the intrinsic defenses of solid tumors.
"We have demonstrated that these tissue-resident natural killer cells exhibit significantly enhanced infiltration into solid tumors compared to their conventional counterparts," stated Dr. John Sunwoo, the Edward C. and Amy H. Sewall Professor in the School of Medicine and senior author of the study. "The results were consistently reproducible, remarkably striking, and unequivocally clear, suggesting a significant leap forward in our ability to harness NK cell therapy for solid malignancies."
The study’s co-lead authors, Dr. Nina Horowitz, a former doctoral student in otolaryngology, Dr. Imran Mohammad, a postdoctoral fellow in the Sunwoo lab, and Dr. June Ho Shin, a senior scientist in the Sunwoo lab, played pivotal roles in this intricate research endeavor. Their collective efforts were instrumental in dissecting the complex biology of NK cells and devising the innovative engineering strategy.
Natural Killer Cells: A Renewed Hope Against Solid Tumors
The experimental therapy, rigorously tested in preclinical models using mice, demonstrated a notable ability to impede the growth of various solid tumor types. The efficacy of these modified NK cells was further amplified when administered in conjunction with an antibody treatment. This combination therapy acts synergistically, with the antibody serving as a beacon, guiding the engineered NK cells more directly to their cancer cell targets.
Beyond their enhanced tumor-fighting capabilities, these engineered NK cells offer a significant practical advantage that could democratize access to advanced cell therapies. Unlike many current immunotherapies that require personalized manufacturing from a patient’s own cells – a process that is time-consuming, expensive, and logistically complex – NK cells typically do not elicit an adverse immune reaction when transferred between individuals. This characteristic opens the door for the development of an "off-the-shelf" therapeutic product. Such a product could be manufactured in large batches, cryopreserved, and readily available for immediate administration to a wide range of patients, significantly reducing treatment delays and potentially lowering costs.
"The prospect of an ‘off-the-shelf’ drug is incredibly exciting," Dr. Sunwoo remarked. "It has the potential to make cell therapy far more accessible to a broader spectrum of patients who may not have been candidates for existing personalized treatments."
The Significance of Tissue-Resident Immune Cells
Natural killer cells, first identified in the 1970s, earned their name from their innate ability to swiftly recognize and eliminate abnormal cells, including cancerous growths and virus-infected cells. A key distinction of NK cells from other lymphocytes, such as B cells and T cells, is their "innate" immune function. They do not require prior sensitization or encounter with a specific antigen to mount an attack, allowing for immediate responses to emergent threats.
For decades, immunological research predominantly focused on immune cells circulating within the bloodstream. These migratory immune cells, including B cells, T cells, and NK cells, continuously patrol the body, seeking out infections and disease. However, a growing body of research has highlighted the critical role of immune cells that reside within specific tissues, where they adapt to their local microenvironment and assume specialized functions.
"Historically, the study of immunology and disease in humans has been heavily concentrated on circulating immune cells," Dr. Sunwoo explained. "With advancements in sophisticated tools and bioinformatics, we are now increasingly exploring the dynamic processes occurring within tissues. It is increasingly evident that for most immune cells, the tissue is where the most critical immune actions take place."
Tissue-resident NK cells are found in various anatomical locations, including the skin, mucous membranes, lungs, and liver. Understanding their precise functions has been a complex endeavor, with previous studies yielding seemingly contradictory results. Some research suggested these resident cells possessed weaker cytotoxic capabilities and could even suppress immune activity, while others indicated they were highly effective at destroying target cells.
Dr. Sunwoo elaborated on this apparent paradox: "These cells may adopt different functions based on specific cues within their microenvironment and the surrounding tissue, leading to differentiation into distinct sub-populations." This plasticity is crucial. In certain physiological contexts, such as early pregnancy, immune-suppressing tissue-resident NK cells in the uterine lining play a vital role in preventing the maternal immune system from rejecting the fetus and supporting placental development. Conversely, cancer treatment necessitates a more aggressive, tumor-icidal phenotype.
Unlocking the Cellular Recipe for Potent Killers
Evidence had suggested the existence of at least two distinct types of tissue-resident NK cells, but the mechanisms governing their development and the reasons for their divergent functional profiles remained elusive. To unravel these mysteries, Dr. Sunwoo’s team embarked on a series of experiments. They isolated circulating NK cells from healthy human blood donors and subjected them to various combinations of cellular signals designed to mimic the complex microenvironments they might encounter in tissues.
A pivotal factor identified in this process was transforming growth factor beta (TGF-β). This signaling protein, produced by a multitude of cell types, including tumor cells, plays a critical role in cellular differentiation and development. The researchers discovered that the quantity and duration of TGF-β signaling were paramount in determining the functional outcome of the NK cells.
"It’s akin to a ‘Goldilocks’ scenario," Dr. Sunwoo explained. "If NK cells receive just the right amount of a TGF-β signal, they differentiate into tissue-resident cells with potent cytotoxic activity against malignant cells. However, if they are exposed to excessive TGF-β, they remain tissue-resident but become inhibited, dysfunctional, and lose their killing capacity. The TGF-β signal must be presented to the NK cells in precisely the correct amount and manner."
While TGF-β was essential for inducing the tissue-resident phenotype, prolonged exposure consistently resulted in NK cells with diminished killing ability. A more effective approach emerged when the researchers exposed NK cells to short-lived human epithelial tumor cells. These tumor cells provided a transient burst of active TGF-β, successfully generating tissue-resident NK cells that exhibited robust tumor-killing activity. Crucially, direct physical contact between the NK cells and the epithelial tumor cells was also found to be indispensable, suggesting that additional activating signals were transmitted through this interaction, beyond soluble factors alone.
"These two populations of tissue-resident NK cells appear very similar morphologically and share some developmental requirements, yet their functional outcomes are diametrically opposed," Dr. Sunwoo noted, highlighting the delicate balance that dictates their ultimate role.
Distinguishing the Most Potent Cancer-Killing Cells
A detailed comparative analysis of the two distinct types of tissue-resident NK cells revealed key molecular differences that underpinned their functional disparity. Both populations expressed surface proteins CD49a and CD103, markers associated with tissue residency. However, only the highly effective cancer-killing cells uniquely expressed CD39.
Furthermore, the more potent NK cell variant contained a significantly greater abundance of the molecular machinery required for target cell destruction. This included higher levels of perforin, a pore-forming protein that creates entry points in target cells, and granzyme A, a cytotoxic molecule delivered through these perforations to induce programmed cell death. These molecular disparities provide a clear explanation for the enhanced tumor-killing capacity of the engineered NK cells.
Slowing Tumor Growth in Preclinical Models
With a reliable method established for generating the more aggressive, tissue-resident NK cells, the research team proceeded to evaluate their ability to infiltrate and combat solid tumors in vivo. In laboratory settings, the engineered cells demonstrated a remarkable capacity to penetrate tumor organoids grown in culture dishes. When subsequently injected into mice bearing established solid tumors, these modified NK cells significantly slowed tumor growth over periods of days and weeks. The observed anti-tumor effects were evident across multiple tumor types, including those derived from human melanoma and head and neck squamous cell carcinoma.
The most compelling results were observed when the engineered NK cells were administered in combination with cetuximab, a monoclonal antibody that targets specific cancer cell surface receptors, marking them for immune attack. Cetuximab is an established therapeutic agent approved for the treatment of metastatic colorectal cancer and advanced head and neck squamous cell carcinoma, although its efficacy as a monotherapy is often limited.
In the mouse models, a single dose of the combination therapy—engineered NK cells plus cetuximab—suppressed tumor growth far more effectively over a one-month period than either treatment administered alone. Importantly, no apparent adverse side effects were observed with the combination therapy.
"Remarkably, even at day 30, when mice receiving other treatments showed signs of illness, those that received the combination therapy appeared very healthy," Dr. Sunwoo reported. He cautiously added, however, that these findings represent a critical proof of concept and cautioned against direct extrapolation to human patients.
Paving the Way for an "Off-the-Shelf" Cell Therapy
Building on these promising preclinical results, Dr. Sunwoo and his colleagues are actively preparing to initiate a Phase I clinical trial to evaluate the safety and efficacy of this combination therapy in human patients with advanced squamous cell carcinoma. Pending approval from the Food and Drug Administration (FDA), this trial could commence by the end of the current year, marking a significant milestone in translating this research from the laboratory to the clinic.
Dr. Sunwoo has also developed and applied for a patent on a method for the large-scale production and expansion of these modified NK cells, technically referred to as cytotoxic tissue-resident natural killer cells. This proprietary process is designed to ensure the consistent generation of therapeutic-grade cells in sufficient quantities for clinical application.
According to the research team, NK cells collected from a single donor could potentially yield approximately 20 treatment doses within a two-week timeframe. This rapid and scalable production capability is central to the vision of an accessible, "off-the-shelf" therapy.
"These cells would be cryopreserved, allowing us to manufacture numerous doses and administer them to different patients without delay," Dr. Sunwoo emphasized. "This would eliminate the significant waiting periods often associated with personalized cell therapies, ensuring timely treatment for those who need it most."
The collaborative nature of this research underscores the collective effort in advancing cancer immunology. Contributions to this significant work were also made by researchers from Ohio State University and Washington University School of Medicine. The study received vital funding from the National Institutes of Health (grants R35DE0130054, K22CA282364, and R25DC020174), the Tai Tsun Wu Research Fund for Natural Killer Cell Immunotherapy, and the Stanford Bio-X Fellowship, all of which were instrumental in enabling this groundbreaking research.
